The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 06, 2007

Filed:

Sep. 24, 2002
Applicants:

Renuka Pillutla, Bridgewater, NJ (US);

Olga Dedova, Highland Park, NJ (US);

Arthur J. Blume, East Greenwich, RI (US);

Neil I. Goldstein, Maplewood, NJ (US);

Renee Brissette, Clarksburg, NJ (US);

Pinger Wang, North Brunswick, NJ (US);

Hao Liu, Pennington, NJ (US);

Ku-chuan Hsiao, Easton, PA (US);

Michael Lennick, Exton, PA (US);

Paul Fletcher, Cheshire, CT (US);

Inventors:

Renuka Pillutla, Bridgewater, NJ (US);

Olga Dedova, Highland Park, NJ (US);

Arthur J. Blume, East Greenwich, RI (US);

Neil I. Goldstein, Maplewood, NJ (US);

Renee Brissette, Clarksburg, NJ (US);

Pinger Wang, North Brunswick, NJ (US);

Hao Liu, Pennington, NJ (US);

Ku-Chuan Hsiao, Easton, PA (US);

Michael Lennick, Exton, PA (US);

Paul Fletcher, Cheshire, CT (US);

Assignees:

Antyra Inc., Edison, NJ (US);

Novo Nordisk A/S, Bagsvaerd, DK;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
Abstract

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.


Find Patent Forward Citations

Loading…